Keystone Symposia

Whistler Conference Centre Floorplan

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019

Here are the related meetings in 2021:
Advances in Cancer Immunotherapy (EK1)
Myeloid Cells and Innate Immunity in Solid Tumors (EK4)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

Organizer(s) Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege
March 10—14, 2019
Whistler Conference Centre • Whistler, BC Canada
Discounted Abstract Deadline: Nov 20, 2018
Abstract Deadline: Dec 5, 2018
Scholarship Deadline: Nov 20, 2018
Discounted Registration Deadline: Jan 15, 2019

Sponsored by Autolus Therapeutics, Bayer AG, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, ImmunoGen, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., Roche, Surface Oncology, TESARO, Inc., Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.

Summary of Meeting:
Cancer immunotherapy is an established field that has led to remarkable clinical benefit for a subset of patients. However, a deeper understanding of the mechanisms of response and resistance to current immunotherapy strategies is needed to help develop new treatments that will increase the number of patients who will benefit. This Keystone Symposia conference is focused on immunotherapy as a treatment for cancer, including potential combination therapies and development of new technologies to elucidate novel targets and/or biomarkers that will be used to design new treatments and enable appropriate patient selection to improve clinical outcomes for cancer patients. The conference will bring together leading and emerging scientists to advance the development of new immune-based treatments for cancer. Discussions will also consider the future directions of the field, including the identification of the most pressing unanswered questions, the areas needing more focus, and those that would benefit from new approaches and methodologies developed and used in other related fields.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time

The meeting will begin on Sunday, March 10 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 14 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 15 in order to fully experience the meeting.


Arrival and Registration

Grand Foyer
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Grand Foyer



Grand Foyer
Welcome and Keynote Address

Sea to Sky B/C
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

Catherine J. Wu, Dana-Farber Cancer Institute, USA
Identifying and Targeting Tumor Neoantigens

Response and Resistance Mechanisms to Cancer Immunotherapy

Sea to Sky B/C
* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Coffee Break

Philip D. Greenberg, University of Washington, USA
Resistance Mechanisms to Engineered T Cell Therapies

* Robert D. Schreiber, Washington University School of Medicine, USA
The Molecular Cell Biology of Immune Control and Escape of Cancer

Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma

Robert T. Manguso, Massachusetts General Hospital, USA
Short Talk: Loss of ADAR1 in Tumors Overcomes Resistance to Immune Checkpoint Blockade

On Own for Lunch

Poster Setup

Sea to Sky A
Poster Viewing

Sea to Sky A
Workshop 1: Engaging New Mechanisms to Improve Cancer Immunotherapy

Sea to Sky B/C
Donald E. Staunton, Arbele Corporation, USA
Bispecific CDH17/CD3 Antibodies with High Tumor Specificity, Cytotoxicity and Safety in Non-Human Primates

Krzysztof Masternak, NovImmune SA, Switzerland
CD47-Blocking Bispecific Antibodies Increase in vivo Phagocytosis of Tumor Cells and Modify the Tumor Microenvironment

Limei Shen, University of North Carolina, USA
Nano-trapping B Cell Chemoattractant CXCL13 Reduces Bregs in Tumor Microenvironment and Inhibits Desmoplastic Tumors in Murine Orthotopic Models

Adrienne H. Long, Dana-Farber Cancer Institute, USA
Inhibition of Signal Peptide Peptidase Triggers Novel Antigen Presentation on Non-Classical MHC and Sensitizes Tumors to Checkpoint Blockade

* Shruthy Suresh, University of Texas Southwestern Medical Center, USA
The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung Cancer

Andrew G. Thomason, Redx Pharma, UK
Wnt Pathway Suppression with Porcupine Inhibitor RXC004 Enhances the Immune Response against Tumours

* Patrick A. Ott, Dana-Farber Cancer Institute, USA
Complex Inter-Relationship of Body Mass Index, Gender and Serum Creatinine on Survival: Exploring the Obesity Paradox in Melanoma Patients Treated with Immune Checkpoint Inhibition

Coffee Available

Grand Foyer
Technological Advances for Dissecting Immune Responses

Sea to Sky B/C
* Elaine R. Mardis, Nationwide Children's Hospital, USA
Genomic Exploration of the Pediatric CNS Tumor Microenvironment

* Michael Angelo, Stanford University, USA
Mapping the Immune Landscape in Solid Tumors using MIBI

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Therapy: Lessons Learned and Next Steps

Jonathan Fisher, University College London, UK
Short Talk: Mass Cytometric Analysis of CAR Signaling – Single Cell Engine Diagnostics Reveals Problems and Solutions

Martin LaFleur, Harvard Medical School, USA
Short Talk: CHIME: A Chimeric CRISPR-Cas9 Delivery System for Pooled in vivo Screening of Genes in the Immune System

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky A
Poster Session 1

Sea to Sky A



Grand Foyer
Improving Anti-Tumor Immune Responses

Sea to Sky B/C
* Aviv Regev, Genentech, USA
Comprehending Anti-Tumor Immune Responses through Single-Cell Studies

Elizabeth G. Trehu, Jounce Therapeutics, USA
Lessons Learned from Clinical Trials Targeting ICOS

Coffee Break

Thomas Gajewski, University of Chicago, USA
Identifying Mechanisms to Facilitate a T Cell-Inflamed Tumor Microenvironment

* Niroshana Anandasabapathy, Weill Cornell Medicine, USA
Targeting T Cell:DC Cross Talk in the Periphery to Expand Anti-Tumor Immunity

Shannon K. Oda, Fred Hutchinson Cancer Research Center, USA
Short Talk: A Fas-4-1BB Immunomodulatory Fusion Protein Enhances Function and Metabolism of Engineered T cells and Improves Immunotherapy of Liquid and Solid Tumors

On Own for Lunch

Poster Setup

Sea to Sky A
Poster Viewing

Sea to Sky A
Workshop 2: Engineered T Cells

Sea to Sky B/C
Mauro Castellarin, University of Pennsylvania, USA
A Universal Chimeric Antigen Receptor System for Switching Target Recognition by CAR T Cells

Philip S. Low, Purdue University, USA
Evaluation of a Universal CAR T Cell Technology in Murine Tumor Models

Louai Labanieh, Stanford University, USA
Controlling CAR-T Function with an FDA-Approved Small Molecule

Henri Bayle, Bellicum Pharmaceuticals, USA
Control of CAR-Natural Killer Cell Expansion and Anti-Tumor Activity with Inducible MyD88/CD40 and Small Molecules

Tori Yamamoto, NCI, University of Pennsylvania, USA
T Cells Engineered to Overcome Death Signaling within the Tumor Microenvironment Enhance Adoptive Cancer Immunotherapy

Robert J. Hofmeister, TCR2 Therapeutics, USA
Preclinical Evaluation of TC-210, a Mesothelin-Specific T Cell Receptor (TCR) Fusion Construct (TRuC™) T Cells for the Treatment of Solid Tumors

* Beatrice Greco, Vita-Salute San Raffaele University, Italy
Combining De-Glycosylating Agents with CAR-T Cells for Targeting Solid Tumors and Reducing Toxicity

* Melody Smith, Memorial Sloan Kettering Cancer Center, USA
Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy

Coffee Available

Grand Foyer
Engineering T Cells

Sea to Sky B/C
* Crystal L. Mackall, Stanford University, USA
Engineering Exhaustion Resistant T Cells to Enhance the Efficacy of CAR-Based Therapies

* Kristen Hege, Celgene, USA
Clinical Development of BCMA CAR T Cells in Myeloma

Carl H. June, University of Pennsylvania, USA
CAR T Cell Therapies: Lessons Learned and Next Steps

Megan M. Dacek, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Potentiating Innate and Adaptive Immunity with Engineered CAR T Cells

Evan William Weber, Stanford University, USA
Short Talk: Transient Rest Reverses CAR T Cell Exhaustion and Augments Efficacy

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky A
Poster Session 2

Sea to Sky A



Grand Foyer
Immune Checkpoints: Basic Mechanisms and Novel Targets

Sea to Sky B/C
Chris H. Takimoto, Forty Seven, Inc., USA
Enhancing Antitumor Immunity by Inhibiting CD47 Signaling: An Overview of CD47 Targeting Agents in Clinical Development

* Sangeeta Goswami, MD Anderson Cancer Center, USA
Modulation of Immune Checkpoint Therapy Responses by Immune Cell Inherent Epigenetic Machinery

Coffee Break

Willem W. Overwijk, Nektar Therapeutics, USA
Intratumoral Expansion of CD8+ T cells and Depletion of Tregs after Treatment with NKTR-214, a First-In-Class, CD122-Preferential IL-2 Pathway Agonist

* Xiaoyan Michelle Zhang, Kyn Therapeutics, USA
Kynureninase and AHR Inhibition, Novel and Differentiated Approaches Targeting IDO1/TDO2/Kynurenine Pathway and Beyond

Martina Seiffert, German Cancer Research Center, Germany
Short Talk: IL-10/STAT3 Signaling Overcomes Tumor-Induced Exhaustion of CD8+ T-Cells

Dana Emerson, Oregon Health and Science University, USA
Short Talk: ITK Inhibition Augments the Therapeutic Efficacy of anti-OX40/anti-CTLA-4 Immunotherapy via Enhanced Eomes Expression and Effector T-Cell Responses

Tao Dong, University of Oxford, UK
Short Talk: A Comprehensive Analysis of Key Immune Checkpoint Receptors on T Cells Indicates Mono-or Combinatorial Blockade Immunotherapy in Multiple Types of Cancer

On Own for Lunch

Poster Setup

Sea to Sky A
Poster Viewing

Sea to Sky A
Coffee Available

Grand Foyer
Combinatorial Immunotherapy Strategies

Sea to Sky B/C
* Sandra Demaria, Weill Cornell Medical College, USA
Using Precision Radiotherapy to Ignite Anti-Tumor Immunity with Immunotherapy

Juan C. Jaen, Arcus Biosciences, Inc., USA
Targeting Immune Activation via Inhibition of the Adenosine Pathway

* Antoni Ribas, University of California, Los Angeles, USA
Novel Combination Therapy Strategies

Peter Goff, University of Washington, USA
Short Talk: Newcastle Disease Virus Works Synergistically with Radiotherapy to Enhance Checkpoint Blockade and Improve Long-Term Survival in a Murine Melanoma Model

Sarah L. Buchan, University of Southampton, UK
Short Talk: PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs that Synergize for CD8+ T-Cell Driven Anti-Tumor Immunity

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky A
Poster Session 3

Sea to Sky A



Grand Foyer
Progress Report on Immune Monitoring and Clinical Trials

Sea to Sky B/C
Robert H. Vonderheide, University of Pennsylvania, USA
Immunogenic Properties of Mutant KRAS

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Regulation of Immune Recognition by the CD47 and PD-L1 Immune Checkpoints

Coffee Break

* Sumit Kumar Subudhi, MD Anderson Cancer Center, USA
Immune Checkpoint Therapies in Prostate Cancer

* Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
Therapeutic Vaccination for Intraepithelial Disease: Lessons Learned from HPV

Hideho Okada, University of California, San Francisco, USA
Short Talk: Targeting H3.3 K27M Mutation as a Shared Neoantigen in HLA-A*0201+ Patients with Diffuse Midline Gliomas – Development of a Novel Mass Cytometry-Based Monitoring of Vaccine-Reactive, Epitope-Specific CD8+ T Cell Responses

Akil A. Merchant, Cedars-Sinai Medical Center, USA
Short Talk: Highly Multiplexed Imaging Mass Cytometry Reveals Immune Cell Composition and Spatial Heterogeneity in Diffuse Large B Cell Lymphoma Associated with Treatment Outcome

Colleen Annesley, Seattle Children's Hospital, USA
Short Talk: Novel CD19t T-Antigen-Presenting Cells Expand CD19 CAR T Cells in vivo

On Own for Lunch

Workshop 3: Engineering Novel Therapeutic Agents

Sea to Sky B/C
Michael Schebesta, Obsidian Therapeutics, USA
Enhancing Adoptive Cell Therapies Through Regulation of CD40L

* Nadia Coltella, Universita' Vita-Salute San Raffaele, Italy
Development of Chimeric Forms of IFN-α for Inducible in vivo Cancer Gene Therapy

Sriram Sathyanarayanan, Codiak BioSciences, USA
Developing an Engineered Exosome Therapeutic Platform for Immuno-Oncology

Chris Saxby, University of Washington, USA
Engineered Cytokine Receptors Support CAR T Cell Mediated Tumor Removal

* Sara Schad, Memorial Sloan Kettering Cancer Center, USA
Phosphatidylserine Targeting Antibody Enhances Anti-Tumor Activity of CAR T Cell Therapy in a Mouse Melanoma Model

Scott T. Walsh, NCI, National Institutes of Health, USA
Development of a Novel Interleukin-7 Hydrogel Delivery System for T cell Applications

Coffee Available

Grand Foyer
The Future of Cancer Immunotherapy

Sea to Sky B/C
* Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy

* Michael C. Jensen, Seattle Children's Research Institute, USA
Regulating the Next Generation of Genetically Enhanced CAR T Cells

Flavius Martin, Amgen, Inc., USA
Learnings from Bispecific T-Cell Engagers, from Bedside Back to the Bench

Darren Austin Plumb, PsiOxus Therapeutics, UK
Short Talk: Development of an Oncolytic T-SIGn Virus, NG-641, Targeting Cancer-Associated Fibroblasts for the Treatment of Stroma-Rich Carcinomas

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Sea to Sky B/C
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Sea to Sky A
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Sea to Sky A



*Session Chair †Invited, not yet responded.

We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Autolus Therapeutics Bayer AG
BioLegend, Inc. Bristol-Myers Squibb Company
Cell Research ImmunoGen, Inc.
Incyte Corporation MedImmune
Merck & Co., Inc. Roche
Surface Oncology Takeda Pharmaceutical Company Limited
TESARO, Inc. Tessa Therapeutics Ltd.

We gratefully acknowledge additional support from these exhibitors at this conference:

PeproTech, Inc. 10x Genomics
Please stop by to meet these exhibitors during the conference.

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

Grant No. 1R13CA236284-01

Funding for this conference was made possible (in part) by 1R13CA236284-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) American Society of Gene & Cell Therapy (ASGCT)
eLife InSphero Inc.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Amgen Inc.

Arcus Biosciences, Inc.

Celgene Corporation

Forty Seven, Inc.

Jounce Therapeutics, Inc.

Kyn Therapeutics

Nektar Therapeutics

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email:,
Phone:+1 970-262-1179